Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

被引:23
|
作者
Timmins, Hannah C. [1 ]
Mizrahi, David [2 ]
Li, Tiffany [1 ]
Kiernan, Matthew C. [1 ,3 ,4 ]
Goldstein, David [2 ,5 ]
Park, Susanna B. [1 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[2] UNSW Sydney, Fac Med, Prince Wales Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW, Australia
[5] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Chemotherapy; Neuropathy; Risk factors; Obesity; Diabetes; Physical activity; QUALITY-OF-LIFE; CANCER-PATIENTS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; BREAST-CANCER; SENSORY NEUROPATHY; BODY-MASS; EXERCISE; SURVIVORS; WOMEN;
D O I
10.1007/s11764-021-00988-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. Methods Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. Results Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. Conclusions Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. Implications for Cancer Survivors Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
引用
收藏
页码:222 / 236
页数:15
相关论文
共 50 条
  • [21] Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review
    Wang, Mian
    Pei, Ziwen
    Molassiotis, Alex
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2022, 58
  • [22] Severity, Risk Factors and Quality of Life of Patients associated with Chemotherapy-Induced Peripheral Neuropathy
    Srivastava, Saumya P.
    Sinha, Aditi Prashant
    Sharma, Kamlesh Kumari
    Malik, Prabhat Singh
    CLINICAL NURSING RESEARCH, 2022, 31 (06) : 1080 - 1090
  • [23] Effect of exercise on gait and postural control in patients with chemotherapy induced peripheral neuropathy: a systematic review
    Yeasmin, Shahnaz
    Azharuddin, Muhammad
    SPORT SCIENCES FOR HEALTH, 2024, 20 (03) : 693 - 700
  • [24] Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial
    Bland, Kelcey A.
    Kirkham, Amy A.
    Bovard, Joshua
    Shenkier, Tamara
    Zucker, David
    McKenzie, Donald C.
    Davis, Margot K.
    Gelmon, Karen A.
    Campbell, Kristin L.
    CLINICAL BREAST CANCER, 2019, 19 (06) : 411 - 422
  • [25] Exercise intervention for the management of chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis
    Nakagawa, Natsuki
    Yamamoto, Sena
    Hanai, Akiko
    Oiwa, Ayano
    Arao, Harue
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [26] Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review
    Konuma, Masanori
    Ikeda, Tomohiro
    Mitoma, Tomohiro
    Shirakawa, Shinsuke
    Maki, Jota
    Katayama, Yoshimi
    Hamada, Masanori
    Nagao, Shoji
    Ozaki, Toshifumi
    GYNECOLOGIC ONCOLOGY, 2025, 192 : 155 - 162
  • [27] Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations
    Hou, Saiyun
    Huh, Billy
    Kim, Hee Kee
    Kim, Kyung-Hoon
    Abdi, Salahadin
    PAIN PHYSICIAN, 2018, 21 (06) : 571 - 592
  • [28] Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings
    Ibrahim, Eiman Y.
    Ehrlich, Barbara E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
  • [29] Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review
    Brami, Cloe
    Bao, Ting
    Deng, Gary
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 98 : 325 - 334
  • [30] Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer A Secondary Analysis of a Randomized Clinical Trial
    Cao, Anlan
    Cartmel, Brenda
    Li, Fang-Yong
    Gottlieb, Linda T.
    Harrigan, Maura
    Ligibel, Jennifer A.
    Gogoi, Radhika
    Schwartz, Peter E.
    Esserman, Denise A.
    Irwin, Melinda L.
    Ferrucci, Leah M.
    JAMA NETWORK OPEN, 2023, 6 (08) : e2326463